BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND FANCG, ENSG00000221829, 2189, O15287, XRCC9, FAG
25 results:

  • 1. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.
    Chen Y; Chen D; Wang Q; Xu Y; Huang X; Haglund F; Su H
    Front Immunol; 2021; 12():719105. PubMed ID: 35111149
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The identification of six risk genes for ovarian cancer platinum response based on global network algorithm and verification analysis.
    Xing L; Mi W; Zhang Y; Tian S; Zhang Y; Qi R; Lou G; Zhang C
    J Cell Mol Med; 2020 Sep; 24(17):9839-9852. PubMed ID: 32762026
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature.
    Morrison A; Nasioudis D
    Gynecol Oncol; 2020 Aug; 158(2):476-483. PubMed ID: 32513565
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Molecular predictors for the course of disease and individualized therapy in pancreatic cancer].
    Damanakis AI; Gebauer F; Bruns CJ
    Chirurg; 2020 Aug; 91(8):642-649. PubMed ID: 32405728
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
    Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
    Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The role of age in pancreatic intraductal papillary mucinous neoplasms of the pancreas: Same risk of death but different implications for management.
    Marchegiani G; Andrianello S; Perri G; Pollini T; Caravati A; Secchettin E; Malleo G; Bassi C; Salvia R
    Dig Liver Dis; 2018 Dec; 50(12):1327-1333. PubMed ID: 29941281
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian cancer.
    Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
    Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
    Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature.
    Almeida JP; Ruiz-Treviño AS; Liang B; Omay SB; Shetty SR; Chen YN; Anand VK; Grover K; Christos P; Schwartz TH
    J Neurosurg; 2018 Aug; 129(2):404-416. PubMed ID: 28862548
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A comparison of overall survival with 40 and 50mg/m
    Nakayama M; Kobayashi H; Takahara T; Nishimura Y; Fukushima K; Yoshizawa K
    Gynecol Oncol; 2016 Nov; 143(2):246-251. PubMed ID: 27612976
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.
    Lal S; Zarei M; Chand SN; Dylgjeri E; Mambelli-Lisboa NC; Pishvaian MJ; Yeo CJ; Winter JM; Brody JR
    Sci Rep; 2016 Sep; 6():33323. PubMed ID: 27616351
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The Relationship between Intraoperative Rupture and Recurrence of Pediatric Ovarian Neoplasms: Preliminary Observations.
    Yousef Y; Pucci V; Emil S
    J Pediatr Adolesc Gynecol; 2016 Apr; 29(2):111-6. PubMed ID: 26300232
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
    Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
    Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study.
    Reuwer AQ; Sondermeijer BM; Battjes S; van Zijderveld R; Stuijver DJ; Bisschop PH; Twickler MT; Meijers JC; Schlingemann RO; Stroes ES
    Pituitary; 2012 Dec; 15(4):472-81. PubMed ID: 21993601
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
    van der Heijden MS; Brody JR; Dezentje DA; Gallmeier E; Cunningham SC; Swartz MJ; DeMarzo AM; Offerhaus GJ; Isacoff WH; Hruban RH; Kern SE
    Clin Cancer Res; 2005 Oct; 11(20):7508-15. PubMed ID: 16243825
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
    Macleod K; Mullen P; Sewell J; Rabiasz G; Lawrie S; Miller E; Smyth JF; Langdon SP
    Cancer Res; 2005 Aug; 65(15):6789-800. PubMed ID: 16061661
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer.
    Couch FJ; Johnson MR; Rabe K; Boardman L; McWilliams R; de Andrade M; Petersen G
    Cancer Res; 2005 Jan; 65(2):383-6. PubMed ID: 15695377
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Functional defects in the fanconi anemia pathway in pancreatic cancer cells.
    van der Heijden MS; Brody JR; Gallmeier E; Cunningham SC; Dezentje DA; Shen D; Hruban RH; Kern SE
    Am J Pathol; 2004 Aug; 165(2):651-7. PubMed ID: 15277238
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot.
    Van Der Heijden MS; Brody JR; Kern SE
    Cancer Biol Ther; 2004 Jun; 3(6):534-7. PubMed ID: 15107617
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The genetics of FANCC and fancg in familial pancreatic cancer.
    Rogers CD; van der Heijden MS; Brune K; Yeo CJ; Hruban RH; Kern SE; Goggins M
    Cancer Biol Ther; 2004 Feb; 3(2):167-9. PubMed ID: 14726700
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.